Lineweaver Wealth Advisors LLC Makes New Investment in Agilent Technologies, Inc. $A

Lineweaver Wealth Advisors LLC purchased a new stake in shares of Agilent Technologies, Inc. (NYSE:A) in the second quarter, according to its most recent disclosure with the SEC. The firm purchased 3,795 shares of the medical research company’s stock, valued at approximately $448,000.

Several other hedge funds also recently modified their holdings of A. Valeo Financial Advisors LLC boosted its stake in Agilent Technologies by 3.0% during the first quarter. Valeo Financial Advisors LLC now owns 3,449 shares of the medical research company’s stock valued at $403,000 after buying an additional 102 shares in the last quarter. Cary Street Partners Financial LLC raised its position in Agilent Technologies by 2.9% in the first quarter. Cary Street Partners Financial LLC now owns 3,688 shares of the medical research company’s stock worth $431,000 after acquiring an additional 103 shares in the last quarter. Western Pacific Wealth Management LP lifted its holdings in Agilent Technologies by 15.2% in the 1st quarter. Western Pacific Wealth Management LP now owns 873 shares of the medical research company’s stock valued at $102,000 after acquiring an additional 115 shares during the last quarter. Bartlett & CO. Wealth Management LLC boosted its position in shares of Agilent Technologies by 5.1% during the 1st quarter. Bartlett & CO. Wealth Management LLC now owns 2,406 shares of the medical research company’s stock valued at $281,000 after purchasing an additional 116 shares in the last quarter. Finally, Brighton Jones LLC boosted its position in shares of Agilent Technologies by 2.6% during the 1st quarter. Brighton Jones LLC now owns 4,784 shares of the medical research company’s stock valued at $560,000 after purchasing an additional 121 shares in the last quarter.

Agilent Technologies Trading Up 1.2%

NYSE A opened at $127.18 on Wednesday. The firm’s 50 day moving average price is $120.01 and its two-hundred day moving average price is $115.85. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.71 and a current ratio of 2.25. Agilent Technologies, Inc. has a twelve month low of $96.43 and a twelve month high of $153.84. The stock has a market cap of $36.06 billion, a price-to-earnings ratio of 29.85, a PEG ratio of 3.91 and a beta of 1.24.

Agilent Technologies (NYSE:A) last issued its earnings results on Wednesday, August 27th. The medical research company reported $1.37 EPS for the quarter, hitting the consensus estimate of $1.37. Agilent Technologies had a return on equity of 25.51% and a net margin of 17.97%.The business had revenue of $1.74 billion during the quarter, compared to analysts’ expectations of $1.67 billion. During the same quarter last year, the firm posted $1.32 earnings per share. Agilent Technologies’s revenue was up 10.1% compared to the same quarter last year. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. Equities analysts anticipate that Agilent Technologies, Inc. will post 5.58 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms recently commented on A. Evercore ISI dropped their target price on shares of Agilent Technologies from $130.00 to $128.00 and set an “in-line” rating on the stock in a report on Thursday, August 28th. JPMorgan Chase & Co. decreased their price target on shares of Agilent Technologies from $160.00 to $155.00 and set an “overweight” rating on the stock in a research report on Thursday, May 29th. UBS Group cut their price objective on Agilent Technologies from $150.00 to $130.00 and set a “neutral” rating for the company in a research report on Thursday, May 29th. Barclays reissued an “equal weight” rating and set a $125.00 price objective on shares of Agilent Technologies in a research note on Friday, August 29th. Finally, Leerink Partners lifted their target price on Agilent Technologies to $135.00 and gave the stock a “buy” rating in a report on Friday, May 30th. Six investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, Agilent Technologies currently has a consensus rating of “Moderate Buy” and a consensus target price of $140.08.

Insiders Place Their Bets

In other news, CEO Padraig Mcdonnell sold 1,508 shares of the company’s stock in a transaction dated Tuesday, July 1st. The stock was sold at an average price of $117.44, for a total value of $177,099.52. Following the transaction, the chief executive officer owned 37,448 shares in the company, valued at $4,397,893.12. This represents a 3.87% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.